Search alternatives:
largest decrease » marked decrease (Expand Search)
larger decrease » marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
Showing 5,481 - 5,500 results of 5,763 for search '(( ct ((largest decrease) OR (larger decrease)) ) OR ( a ((mean decrease) OR (linear decrease)) ))', query time: 0.75s Refine Results
  1. 5481

    Minigene assay of rare missense VUS in exon 10. by Elina Mercier (22311151)

    Published 2025
    “…<p><b>(a)</b> Position of variants that were tested by minigene assay. …”
  2. 5482

    Isolation and characterization of the <i>clr4–1</i> mutant strain. by Ziyue Liu (381532)

    Published 2025
    “…Data are presented as mean ± SD from three independent experiments. Statistical significance was determined using a one-way ANOVA followed by Dunnett’s multiple comparison test, with WT as the reference sample (*<i>p</i> < 0.05 and **<i>p</i> < 0.01; N.S.: not significant).…”
  3. 5483

    Data Sheet 1_Comparison of the efficacy and safety of different growth factors in the treatment of diabetic foot ulcers: an updated network meta-analysis.docx by Jianzhou Tian (21596621)

    Published 2025
    “…Objective<p>This study aimed to evaluate the efficacy and safety of different growth factors (GFs) in the treatment of diabetic foot ulcers (DFUs) through a network meta-analysis.</p>Methods<p>A systematic search was conducted in PubMed, Embase, The Cochrane Library, and Web of Science to identify randomized controlled trials (RCTs) comparing GFs with standard of care (SOC) or comparing different GFs for the treatment of DFU. …”
  4. 5484

    Figure 2 from Loss of Sorting Nexin 10 Accelerates KRAS-Induced Pancreatic Tumorigenesis by Kohinoor Khan (22206206)

    Published 2025
    “…Statistically significant differences *, <i>P</i> < 0.05; **, <i>P</i> < 0.01; and #, <i>P</i> < 0.001 are represented as mean ± SEM. MW, molecular weight; OD, optical density; PI-A, propidium iodide area.…”
  5. 5485

    Table 2_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
  6. 5486

    Table 4_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
  7. 5487

    Supplementary file 1_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
  8. 5488

    Table 1_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
  9. 5489

    Table 3_Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis.docx by Ling Zhou (51948)

    Published 2025
    “…The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. …”
  10. 5490

    <b>Differences in White Matter Microstructure in Children With Type 1 Diabetes Persist During Longitudinal Follow up: Relation to Dysglycemia</b> by Nelly Mauras (8103110)

    Published 2025
    “…<p dir="ltr">Type 1 diabetes has detrimental effects in white matter microstructure. In a longitudinal study, we investigated if these reported findings change as children grow and enter puberty.…”
  11. 5491

    Table 1_Effect of cholecalciferol on immune and vascular function in non-diabetic chronic kidney disease.docx by Kajal Kamboj (12769602)

    Published 2025
    “…</p>Results<p>In total, 62 subjects were studied. The mean age was 44 ± 12 years with 58% men. TH1 cells decreased from 17% (9%, 27%) to 11% (6%, 16%) (p=0.002) and TH2 cells increased from 9% (5%, 16%) to 16% (10%, 27%) (p=0.001) after cholecalciferol treatment. …”
  12. 5492
  13. 5493

    Table 1_Differential resilience of chickpea’s reproductive organs to cold stress across developmental stages: insights into antioxidant strategies for enhanced fertility.docx by Deeksha Padhiar (21010250)

    Published 2025
    “…Exogenous supplementation with 1 mM ascorbate (AsA) and glutathione (GSH) significantly stimulated pollen germination in cold-stressed plants under in vitro conditions, with a greater effect observed in CS genotypes. …”
  14. 5494

    <b>Tirzepatide Associated with Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1–5 Cli... by Ellen M. Apperloo (20405468)

    Published 2025
    “…</p><p dir="ltr"><i>Conclusions:</i> In this post hoc analysis in people with type 2 diabetes, including those with chronic kidney disease, tirzepatide was associated with clinically relevant decreased UACR versus comparators, suggesting a potential kidney-protective effect.…”
  15. 5495

    Table 2_Differential resilience of chickpea’s reproductive organs to cold stress across developmental stages: insights into antioxidant strategies for enhanced fertility.docx by Deeksha Padhiar (21010250)

    Published 2025
    “…Exogenous supplementation with 1 mM ascorbate (AsA) and glutathione (GSH) significantly stimulated pollen germination in cold-stressed plants under in vitro conditions, with a greater effect observed in CS genotypes. …”
  16. 5496

    Supplementary file 1_Therapeutic efficacy and safety of Xuebijing in traumatic brain injury: systematic review and meta-analysis.docx by Yihan Sun (3432287)

    Published 2025
    “…Background<p>Traumatic brain injury (TBI) represents a major global health challenge. Several clinical studies have suggested that Xuebijing (XBJ)—a patented Chinese botanical drug preparation may confer neuroprotective and anti-inflammatory benefits in TBI. …”
  17. 5497

    Baseline characteristics of the study population. by Vatsala Rajendram (20691806)

    Published 2025
    “…<div><p>Background</p><p>Intravenous immunoglobulin is a replacement therapy for patients living with primary immunodeficiencies. …”
  18. 5498

    Patient disposition. by Vatsala Rajendram (20691806)

    Published 2025
    “…<div><p>Background</p><p>Intravenous immunoglobulin is a replacement therapy for patients living with primary immunodeficiencies. …”
  19. 5499

    Table 1_Waning neutralizing antibodies through 180 days after homologous and heterologous boosters of inactivated COVID-19 vaccine.docx by Zhifei Chen (1740625)

    Published 2025
    “…Participants were recruited from December 2021 to June 2022, with a follow-up period of 180 days. We evaluated humoral immune responses and their longevity by measuring the geometric mean titers (GMTs) of neutralizing antibodies against the SARS-CoV-2 virus at various time points post-boost. …”
  20. 5500

    Factors affecting LLINs usage at household level. by Job Oyweri (22041452)

    Published 2025
    “…Not owning a bed decreased the likelihood of net usage by 13.3% [aOR=0.867 (95% CI = 0.816–0.920), p < 0.001]. …”